Post Marketing Safety of Plus CBD™ Products, a Full Spectrum Hemp Extract: A 2-Year Experience

References

• AER Law - Dietary Supplement and Non-Prescription Consumer Protection Act (AER Law) 2006. Pub. Law No. 109-462 (Dec. 22, 2006).
   Google Scholar
• Alsherbiny MA, Li CG. 2018. Medicinal cannabis—potential drug interactions. Medicines. 6(1):3. doi:10.3390/medicines6010003.
   Google Scholar
• Brown AC. 2017. An overview of herb and dietary supplement efficacy, safety and government regulations in the United States with suggested improvements. Part 1 of 5 series. Food Chem Toxicol. 107(Pt A):449–471. doi:10.1016/j.fct.2016.11.001.
   PubMed Web of Science ®Google Scholar
• Brown JD, Winterstein AG. 2019. Potential adverse drug events and drug–drug interactions with medical and consumer Cannabidiol (CBD) use. JCM. 8(7):989. doi:10.3390/jcm8070989.
   Web of Science ®Google Scholar
• Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S., Cannabidiol in Dravet Syndrome Study Group 2017. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 376(21):2011–2020. doi:10.1056/NEJMoa1611618.
   PubMed Web of Science ®Google Scholar
• DSHEA - Law, P. 1994. Dietary Supplement Health and Education Act of 1994. Public Law, 103, 417.
   Google Scholar
• Elms L, Shannon S, Hughes S, Lewis N. 2019. Cannabidiol in the treatment of post-traumatic stress disorder: a case series. J Altern Complement Med. 25(4):392–397. doi:10.1089/acm.2018.0437.
   Google Scholar
• Epidiolex (cannabidiol) [package insert]. Carlsbad, CA: Greenwich Biosciences, 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf.
   Google Scholar
• FD&C Act - Food, Drug & Cosmetic Act 2006. 21 U.S.C. Part H, Section 761, 379aa-1. p. 377–379.
   Google Scholar
• Grech V. WASP (Write a Scientific Paper) using Excel - 2: Pivot tables Early Hum Dev. 2018. Feb;117:104-109. doi:10.1016/j.earlhumdev.2018.01.003.Epub 2018 Jan 12.
   Google Scholar
• Hazell L, Shakir SA. 2006. Under-reporting of adverse drug reactions. Drug Saf. 29(5):385–396. doi:10.2165/00002018-200629050-00003.
   PubMed Web of Science ®Google Scholar
• Iffland K, Grotenhermen F. 2017. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res. 2(1):139–154. doi:10.1089/can.2016.0034.
   PubMedGoogle Scholar
• Ioannou GN, Boyko EJ, Lee SP. 2006. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999–2002. Am J Gastroenterol. 101(1):76–82. doi:10.1111/j.1572-0241.2005.00341.x.
   PubMed Web of Science ®Google Scholar
• Larsen C, Shahinas J. 2020. Dosage, Efficacy and Safety of Cannabidiol Administration in Adults: A Systematic Review of Human Trials. J Clin Med Res. 12(3):129–141. doi:10.14740/jocmr4090.
   PubMedGoogle Scholar
• Levinson DR, and Inspector General 2012. “Incident Reporting Systems by EMS Do Not Capture Most Patient Harm.”.
   Google Scholar
• Lopez HL, Raub B, Cesareo K, Kedia AW, Sandrock J, Kerksick CM, Ziegenfuss TN. 2020. Effects of hemp extract on markers of wellness, stress resilience and recovery in healthy subjects. J. Dietary Supplements. IN PRESS
   Google Scholar
• Machado Bergamaschi M, Helena Costa Queiroz R, Waldo Zuardi A, Crippa AS. 2011. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf. 6(4):237–249. doi:10.2174/157488611798280924.
   PubMedGoogle Scholar
• Marx TK, Reddeman R, Clewell AE, Endres JR, Béres E, Vértesi A, Glávits R, Hirka G, Szakonyiné IP. 2018. An Assessment of the genotoxicity and subchronic toxicity of a supercritical fluid extract of the aerial parts of hemp. J Toxicol. 2018:8143582. doi:10.1155/2018/8143582.
   PubMed Web of Science ®Google Scholar
• MedDRA 2018. Medical Dictionary for Regulatory Activities. https://meddra.org. Accessed 2019-2020.
   Google Scholar
• Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, et al. 2017. Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther. 175:133–150. doi:10.1016/j.pharmthera.2017.02.041.
   PubMed Web of Science ®Google Scholar
• Powell GE, Seifert HA, Reblin T, Burstein PJ, Blowers J, Menius JA, Painter JL, Thomas M, Pierce CE, Rodriguez HW, et al. 2016. Social media listening for routine post-marketing safety surveillance. Drug Saf. 39(5):443–454. doi:10.1007/s40264-015-0385-6.
   PubMed Web of Science ®Google Scholar
• Radcke S, Dillon JF, Murray AL. 2015. A systematic review of the prevalence of mildly abnormal liver function tests and associated health outcomes. Eur J Gastroenterol Hepatol. 27(1):1–7.
   PubMed Web of Science ®Google Scholar
• Shannon S, Lewis N, Lee H, Hughes S. 2019. Cannabidiol in anxiety and sleep: a large case series. Perm J. 23:18–041. doi:10.7812/TPP/18-041.
   PubMedGoogle Scholar
• Shannon S, Opila-Lehman J. 2015. Cannabidiol oil for decreasing addictive use of marijuana: a case report. Integr Med Clinician’s J. 14(6):31.
   Google Scholar
• Shannon S, Opila-Lehman J. 2016. Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report. Perm J. 20(4):16–005. doi:10.7812/TPP/16-005.
   PubMedGoogle Scholar
• Teeple RC, Caplan JP, Stern TA. 2009. Visual hallucinations: differential diagnosis and treatment. Prim Care Companion J Clin Psychiatry. 11(1):26–32. doi:10.4088/PCC.08r00673.
   PubMedGoogle Scholar
• Tsai HH, Lin HW, Simon Pickard A, Tsai HY, Mahady GB. 2012. Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review. Int J Clin Pract. 66(11):1056–1078. doi:10.1111/j.1742-1241.2012.03008.x.
   PubMed Web of Science ®Google Scholar